Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARNA Arena Pharmaceuticals	$99.99	$97.65	$45.50 ▼ $100.00	$6.17B	0.55	1.56 million shs	107 shs
BIIB Biogen	$126.08 -0.7%	$125.68	$110.04 ▼ $238.00	$18.60B	0.14	1.43 million shs	1.10 million shs
INCY Incyte	$68.37 -3.4%	$64.49	$53.56 ▼ $83.95	$13.71B	0.67	2.01 million shs	3.50 million shs
UTHR United Therapeutics	$284.27 +0.1%	$301.12	$266.98 ▼ $417.82	$12.81B	0.57	447,457 shs	462,927 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARNA Arena Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
BIIB Biogen	-0.66%	-0.76%	-1.14%	-8.88%	-43.83%
INCY Incyte	-3.45%	-0.13%	+5.30%	+12.82%	+10.72%
UTHR United Therapeutics	+0.06%	-2.23%	-9.94%	-7.39%	-10.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARNA Arena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	4.9508 of 5 stars	4.2	5.0	0.0	3.7	3.2	1.7	2.5
INCY Incyte	4.3878 of 5 stars	2.1	3.0	0.0	3.1	3.0	2.5	3.1
UTHR United Therapeutics	4.9949 of 5 stars	4.3	5.0	0.0	4.6	3.4	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARNA Arena Pharmaceuticals	0.00	N/A	N/A	N/A
BIIB Biogen	2.38	Hold	$188.48	49.49% Upside
INCY Incyte	2.22	Hold	$74.53	9.01% Upside
UTHR United Therapeutics	2.69	Moderate Buy	$393.08	38.28% Upside

Current Analyst Ratings Breakdown

Latest ARNA, BIIB, UTHR, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$187.00
6/25/2025	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$205.00 ➝ $213.00
6/23/2025	INCY Incyte	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Perform ➝ Sector Perform	$67.00
6/16/2025	INCY Incyte	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$75.00 ➝ $107.00
6/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00
6/12/2025	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$121.00
6/12/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/11/2025	UTHR United Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$321.00 ➝ $315.00
6/3/2025	INCY Incyte	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/3/2025	INCY Incyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$61.00
6/2/2025	UTHR United Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$405.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARNA Arena Pharmaceuticals	$50K	123,305.67	N/A	N/A	$10.94 per share	9.14
BIIB Biogen	$9.68B	1.91	$22.97 per share	5.49	$114.71 per share	1.10
INCY Incyte	$4.24B	3.12	$0.53 per share	127.91	$17.90 per share	3.82
UTHR United Therapeutics	$2.88B	4.46	$28.40 per share	10.01	$144.34 per share	1.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARNA Arena Pharmaceuticals	-$616.43M	-$10.13	N/A	N/A	N/A	N/A	-69.83%	-62.35%	N/A
BIIB Biogen	$1.63B	$10.13	12.45	7.64	1.00	15.07%	14.03%	8.32%	7/30/2025 (Estimated)
INCY Incyte	$32.62M	$0.32	213.66	10.45	0.60	0.48%	2.77%	1.77%	7/29/2025 (Estimated)
UTHR United Therapeutics	$1.20B	$25.06	11.34	10.34	6.22	40.44%	19.33%	16.73%	7/30/2025 (Estimated)

Latest ARNA, BIIB, UTHR, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/30/2025	Q1 2025	UTHR United Therapeutics	$6.29	$6.63	+$0.34	$6.63	$726.82 million	$794.40 million
4/29/2025	Q1 2025	INCY Incyte	$1.01	$1.16	+$0.15	$0.80	$996.17 million	$1.05 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARNA Arena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARNA Arena Pharmaceuticals	0.05	8.59	8.59
BIIB Biogen	0.27	1.44	1.01
INCY Incyte	0.01	2.04	2.00
UTHR United Therapeutics	N/A	5.46	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARNA Arena Pharmaceuticals	83.77%
BIIB Biogen	87.93%
INCY Incyte	96.97%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ARNA Arena Pharmaceuticals	2.41%
BIIB Biogen	0.18%
INCY Incyte	17.80%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARNA Arena Pharmaceuticals	448	61.66 million	60.17 million	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
INCY Incyte	2,617	193.57 million	159.12 million	Optionable
UTHR United Therapeutics	1,305	45.11 million	40.46 million	Optionable

ARNA, BIIB, INCY, and UTHR Headlines

Recent News About These Companies

UTHR United Therapeutics Corporation - Seeking Alpha

June 27 at 7:22 PM | seekingalpha.com

Insider Selling: United Therapeutics Corporation (NASDAQ:UTHR) EVP Sells 11,000 Shares of Stock

June 27 at 5:55 PM | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by Achmea Investment Management B.V.

June 27 at 8:19 AM | marketbeat.com

Robeco Institutional Asset Management B.V. Buys 34,362 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

June 27 at 5:02 AM | marketbeat.com

Contrasting United Therapeutics (NASDAQ:UTHR) and Journey Medical (NASDAQ:DERM)

June 27 at 2:26 AM | americanbankingnews.com

United Therapeutics’ Ralinepag Study: A Potential Game-Changer in PAH Treatment

June 26 at 12:40 PM | tipranks.com

Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

June 26 at 10:45 AM | zacks.com

3D Systems and TISSIUM Achieve FDA Approval for Innovative 3D-Printed Solution in Peripheral Nerve Repair

June 26 at 9:24 AM | quiverquant.comQ

United Therapeutics Corporation (NASDAQ:UTHR) Director Sells $187,043.55 in Stock

June 26 at 7:12 AM | insidertrades.com

Brokerages Set United Therapeutics Corporation (NASDAQ:UTHR) Price Target at $393.08

June 26 at 2:41 AM | americanbankingnews.com

Insider Sell: Nilda Mesa Sells Shares of United Therapeutics Corp

June 25 at 6:10 PM | gurufocus.com

United Therapeutics Corporation (NASDAQ:UTHR) Director Sells $187,043.55 in Stock

June 25 at 5:46 PM | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) Director Sells 3,036 Shares of Stock

June 25 at 5:46 PM | marketbeat.com

5 Must-Read Analyst Questions From United Therapeutics’s Q1 Earnings Call

June 25 at 1:08 PM | msn.com

Oppenheimer Asset Management Inc. Has $5.28 Million Stock Position in United Therapeutics Corporation (NASDAQ:UTHR)

June 25 at 4:19 AM | marketbeat.com

United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver

June 24, 2025 | bakersfield.comB

United Therapeutics’ Ralinepag Study: A Potential Game-Changer for PAH Treatment

June 24, 2025 | tipranks.com

United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension

June 23, 2025 | businesswire.com

United Therapeutics Corporation (NASDAQ:UTHR) Receives Average Recommendation of "Moderate Buy" from Analysts

June 23, 2025 | marketbeat.com

Retirement Systems of Alabama Sells 11,423 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

June 21, 2025 | marketbeat.com

CWA Asset Management Group LLC Raises Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

June 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARNA, BIIB, INCY, and UTHR Company Descriptions

Arena Pharmaceuticals NASDAQ:ARNA

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Biogen NASDAQ:BIIB

$126.08 -0.84 (-0.66%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$126.00 -0.08 (-0.06%)

As of 06/27/2025 07:59 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Incyte NASDAQ:INCY

$68.37 -2.44 (-3.45%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$68.38 +0.00 (+0.01%)

As of 06/27/2025 06:19 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

United Therapeutics NASDAQ:UTHR

$284.27 +0.18 (+0.06%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$282.42 -1.84 (-0.65%)

As of 06/27/2025 05:34 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time